Literature DB >> 7785924

Structure of the osteopontin gene and its promoter.

S Yamamoto1, N Hijiya, M Setoguchi, K Matsuura, T Ishida, Y Higuchi, S Akizuki.   

Abstract

We cloned the hOPN gene and its 5' upstream region, and analyzed its exon-intron structure and potential regulatory sequences of the promoter region in comparison with those of mouse and porcine homologues. The hOPN gene consists of 7 exons that are similar to those of the mouse gene, although the hOPN gene is longer than the mouse homologue. This difference is attributable to an insertion of about 1750 bp immediately before exon 4 in the hOPN gene. A region of approximately 285 bp immediately upstream of the hOPN transcription initiation site was highly conserved and contained a number of potential cis regulatory consensus sequences. CAT analysis using SCC-3 cells demonstrated that nucleotides at positions -439 to -270, -124 to -80, and -55 to -39 contained cis-acting enhancing elements, in which the -124 to -80 element was much more active than the others. Deletion of the sequences between -474 and -270 localized the cis elements to the sequence at position -439 to -410, whereas the deletion between -124 to -80 localized it to -124 to -115, and -94 to -80 (data not shown). Gel shift analysis using synthesized double-stranded oligonucleotides corresponding to the 30 bp at position -439 to -410 (data not shown), and 10 and 15 bp regions at positions -124 to -115 and -94 to -80, respectively, as probes revealed that each probe formed one or two bands complexed with a nuclear protein prepared from SCC-3 cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785924     DOI: 10.1111/j.1749-6632.1995.tb44619.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response.

Authors:  T Sato; T Nakai; N Tamura; S Okamoto; K Matsuoka; A Sakuraba; T Fukushima; T Uede; T Hibi
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

2.  The first intron of the human osteopontin gene contains a C/EBP-beta-responsive enhancer.

Authors:  Francesca Giacopelli; Nadia Rosatto; Maria Teresa Divizia; Roberto Cusano; Gianluca Caridi; Roberto Ravazzolo
Journal:  Gene Expr       Date:  2003

Review 3.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

Review 4.  Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition.

Authors:  Anne George; Arthur Veis
Journal:  Chem Rev       Date:  2008-10-03       Impact factor: 60.622

5.  Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation.

Authors:  Rajeev S Samant; David W Clark; Rebecca A Fillmore; Muzaffer Cicek; Brandon J Metge; Kondethimmana H Chandramouli; Ann F Chambers; Graham Casey; Danny R Welch; Lalita A Shevde
Journal:  Mol Cancer       Date:  2007-01-16       Impact factor: 27.401

6.  Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.

Authors:  Fahmy T Ali; Mohamed A M Ali; Mayada M A Elgizawy; Ahmed M Elsawy
Journal:  Gut Liver       Date:  2015-07       Impact factor: 4.519

7.  Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B.

Authors:  Ana Luiza Dias Angelo; Lourianne Nascimento Cavalcante; Kiyoko Abe-Sandes; Taísa Bonfim Machado; Denise Carneiro Lemaire; Fernanda Malta; João Renato Pinho; Luiz Guilherme Costa Lyra; Andre Castro Lyra
Journal:  Clinics (Sao Paulo)       Date:  2013-10       Impact factor: 2.365

8.  Identification of significant genes in non-small cell lung cancer by bioinformatics analyses.

Authors:  Xia Ye; Qian Gao; Jie Wu; Lin Zhou; Min Tao
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.